Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted to regulate the quality and safety of therapeutic goods in Australia, has been updated to include a provision for the publication of a list of manufacturers granted a licence for the manufacture of therapeutic goods. This legislative measure addresses the need for transparency and accountability in the manufacture of therapeutic goods, ensuring that only entities meeting stringent quality and safety standards are permitted to produce such goods. The Act, overseen by the Therapeutic Goods Administration under the Department of Health, aims to protect public health by maintaining high standards of therapeutic goods available in the market. The policy objective of this legislative amendment is to enhance consumer confidence and safeguard health outcomes by clearly identifying licensed manufacturers, thereby fostering a regulated and reliable supply chain for therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation and oversight of therapeutic goods in Australia, ensuring that these products meet safety, quality, and efficacy standards before they are made available for consumer use. The Act applies to persons and entities involved in the manufacture, importation, supply, and advertising of therapeutic goods. These entities range from pharmaceutical companies to medical device manufacturers, and the Act covers a broad array of products including medicines, medical devices, blood and blood components, and certain types of in vitro diagnostic products. The geographic reach of this legislation is national, applying across the Commonwealth of Australia and overseen by the Therapeutic Goods Administration (TGA). The Act includes provisions for licensing and registration of therapeutic goods, as well as the authority to take enforcement actions against non-compliance. The Act does not apply to therapeutic goods that are regulated under other specific Australian legislation, such as blood and blood products which are covered under the Commonwealth Blood Authority. Additionally, certain exclusions and exemptions may apply to particular goods or entities, and the scope of application can be extended or restricted through subordinate instruments such as regulations or notices issued under the authority of the Act.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") includes provisions for the regulation of therapeutic goods within Australia. Section 38 of the Act allows the Secretary of the Department of Health to grant licences to entities that meet specified standards for the manufacture of therapeutic goods. This particular notice under section 38 announces the grant of such licences to three entities: ANSTO Nuclear Medicine Pty Ltd, The Pharmaceutical Plant Company Pty Ltd, and the Pharmaceutical Testing Facility PTF Department of Microbiology PathWest Laboratory Medicine WA. These licences are numbered MI-2016-LI-10210-1, MI-2017-LI-07809-1, and MI-2016-LI-09565-1 respectively. The Act imposes several obligations on entities granted a licence to manufacture therapeutic goods. These include adhering to Good Manufacturing Practice (GMP) standards, which are detailed in the Therapeutic Goods (Good Manufacturing Practices) Regulations 2003. Licence holders must maintain records and ensure that their facilities and processes meet the required standards to ensure the safety, quality, and efficacy of the therapeutic goods produced. Additionally, the licence holders must notify the Therapeutic Goods Administration (TGA) of any changes in their manufacturing processes, premises, or any other relevant information that could affect the quality or safety of the goods they produce. Failure to comply with the requirements of the Act and associated regulations can result in serious consequences. Under section 32 of the Act, offences may include the manufacture of therapeutic goods without a valid licence, failure to maintain records as required, or the production of goods that do not meet the required standards. Penalties for contravening the Act can include fines and imprisonment. For instance, under section 32, an individual found guilty of an offence involving the manufacture of therapeutic goods without a valid licence may face a fine of up to $220,000 and/or imprisonment for up to five years. Similarly, a body corporate may be fined up to $1,100,000 for the same offence. Furthermore, the TGA has the authority to take action to suspend or cancel a licence if it is determined that the licence holder is not complying with the regulatory requirements, which could have severe implications for the business operations of the affected entity.